Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Gerhardt Attard (Cancer Institute, University College London, UK), Dr Elena Castro (12 de Octubre University Hospital, Madrid, Spain), and Dr Brigida Maiorano (IRCCS Ospedale San Raffaele, Milan, Italy) discuss the critical role of early genetic testing in metastatic prostate cancer (mPC).

The panel explores recent advancements in prostate cancer, emphasising the importance of identifying genetic alterations, such as BRCA mutations, particularly in metastatic hormone-sensitive disease.

They advocate for earlier genetic testing to guide treatment decisions and improve patient outcomes.

A review of the AMPLITUDE trial highlights the clinical benefit of combining PARP inhibitors with standard therapies to extend progression-free survival.

The discussion also addresses the need to balance efficacy with toxicity management and the importance of mitigating adverse events.

The experts also reflect on data from the CAPTURE study and the IRONMAN registry, offering insights into real-world outcomes and ongoing research efforts.

Looking ahead, the panel expresses optimism about the next generation of PARP inhibitors, which show potential for improved tolerability and reduced toxicity.